Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

Novo Nordisk (NVO) is one of the stocks most watched ... (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, ...

Novo Nordisk (NYSE:NVO) today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for ...

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Should investors buy Novo Nordisk stock? Here is what to know. Patients can't get enough of Novo Nordisk's GLP-1 agonists, which has created headaches for the company The rampant success of GLP-1 ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Novo Nordisk (NVO) has been one of the ... (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued ...

Novo Nordisk announced that its next-generation ... On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.